Search This Blog

Sunday, June 23, 2013

Lilly's Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes (NYSE:LLY)

Lilly's Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.